Skip to main content
. Author manuscript; available in PMC: 2015 Apr 1.
Published in final edited form as: Hepatology. 2014 Mar 1;59(4):1311–1319. doi: 10.1002/hep.26920

Table 1. LDLT and DDLT Recipient Characteristics.

LDLT (n = 195) DDLT (n = 180] P Value*

Median [IQR] or n (%) Median [IQR] or n (%)
Donor Characteristics      
 Age (years) 37 [27-45] 43 [26-51] 0.01
 Age >50 years old 26 (13%) 53 (29%) <0.0001
 Male 104 (53%) 100 (56%) 0.42
 Race/ethnicity     <0.0001
  White 164 (84%) 109 (61%)  
  African American 10 (5%) 31 (17%)  
  Asian 6 (3%) 6 (3%)  
  Hispanic/Latino 15 (8%) 33 (18%)  
 Warm ischemia time (minutes) 36 [30-45] 40 [35-46] 0.004
  Cold ischemia time (minutes) 41 [31-60] 423 [300-560] <0.0001
Recipient Characteristics      
 Age (years) 53 [49-57] 54 [49-58] 0.18
 Male 134 (69%) 130 (72%) 0.46
 Race     0.31
  White 170 (87%) 147 (82%)  
  African American 7 (4%) 11 (6%)  
  Other 18 (9%) 22 (12%)  
 Pretransplant and Peritransplant      
 BMI (kg/m2) 26.8 [24.2-30.2] 26.6 [23.9-30.2] 0.62
 HCC diagnosis 35 (18%) 54 (30%) 0.006
 Diabetes 30 (15%) 39 (22%) 0.12
 Transplant in the MELD Era 110 (56%) 108 (60%) 0.48
 Lab MELD (max 40) 15 [12-18] 19 [14-25] <0.0001
 Albumin (g/dL) 2.8 [2.4-3.2] 2.7 [2.4-3.2] 0.52
 Alkaline phosphatase (IU/L) 124 [92-169] 117 [84-154] 0.27
 ALT (IU/L) 56 [33-89] 46 [30-76] 0.07
 AST (IU/L) 89 [64-136] 79 [56-121] 0.17
 Bilirubin (mg/dL) 2.5 [1.5-4.0] 3.5 [1.8-6.7] 0.0001
 INR 1.5 [1.3-1.7] 1.6 [1.3-2.1] 0.0006
 Creatinine (mg/dL) 0.9 [0.7-1.2] 1.1 [0.8-1.5] 0.0007
Immunosuppressive Therapy      
 At Month 6      
  Tacrolimus 92 (87%) 61 (66%) 0.0004
  Steroid 55 (52%) 51 (55%) 0.68
  Cyclosporine 8 (5%) 21 (23%) 0.002
  MMF 48 (45%) 52 (56%) 0.13
  Sirolimus 9 (8%) 16 (17%) 0.06
 Ever used Sirolimus 59 (30%) 54 (30%) 0.96
Post-Transplant      
 HCV treatment 77 (55%) 61 (48%) 0.27
  SVR 18 (35%) 10 (23%) 0.58
 Treatment of acute rejection 71 (39%) 64 (41%) 0.80
 Biliary complication 84 (46%) 43 (35%) <0.0001
  Bile leak 42 (23%) 17 (10%) 0.001
  Biliary stricture 64 (36%) 31 (19%) 0.0014
 Follow-up (years) 4.94 [2.82-6.93] 4.26 [2.54-6.03] 0.05
*

Chi-square tests for proportions were used for categorical variables, Wilcoxon rank-sum tests were used for continuous variables, log-rank tests for post-transplant variables.

Data available for 106 LDLTs and 93 DDLTs.

Percentages were calculated using Kaplan-Meier estimation.

Abbreviations: MMF, mycophenolate mofetil; SVR, sustained virologic response.